For years, scientists have hoped to use the gene-editing technology CRISPR to help treat all sorts of diseases, including cancer. Now for the first time in the U.S., researchers say they’ve shown that CRISPR-edited immune cells can be safely given to cancer patients and survive for up to nine months—a finding that may signal CRISPR’s future as part of an emerging cancer treatment known as immunotherapy.

Source: U.S. Trial Finds CRISPR-Edited Cells Are Safe in Cancer Patients